Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER vs Olanzapine in Schizophrenia
NCT00083668Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of paliperidone in schizophrenia (5 arms), sponsored by Johnson & Johnson. Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Apr 2004; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00083668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083668.